144 - December 19, 2025 | SEC Filings

Brief

Rocket Lab director Nina Armagno filed Form 144 to sell 27,314 common shares acquired via RSU vesting on 10/30/2025, with aggregate value of $1,636,654.88. The sale follows a Rule 10b5-1 trading plan adopted 09/19/2025, with no prior sales in the past 3 months. This routine insider transaction provides liquidity from compensation with minimal impact given shares outstanding of 534M.

Detailed Brief

Form 144 discloses Nina Armagno, a Rocket Lab director (CIK 0001991365), proposing to sell 27,314 common shares on or around 12/19/2025 through Morgan Stanley. Shares were acquired on 10/30/2025 from vesting restricted stock units issued by Rocket Lab (issuer address: 3881 McGowen St, Long Beach, CA). The filing notes reliance on a Rule 10b5-1 plan established 09/19/2025, certifying no undisclosed material adverse information as of plan date. No securities sold by Armagno in the prior 3 months. As a standard affiliate sale under Rule 144, it reflects typical director compensation practices in the space industry, where RSUs vest periodically for liquidity without signaling operational concerns.

Key Telemetry

• Nina Armagno (Director) to sell 27,314 common shares, market value $1,636,654.88 (~$59.93/share).

• Shares from RSUs vested 10/30/2025; no payment details needed.

• Rule 10b5-1 plan adopted 09/19/2025; sale ~12/19/2025 on NASDAQ.

• No sales by filer in past 3 months; certifies no undisclosed adverse info.

• Negligible volume vs. 534,156,333 shares outstanding (~0.005%).

Impact Vector

Minimal near-term pressure on RKLB stock from this small sale (<<0.01% of float), routine for directors exercising vested RSUs under pre-set 10b5-1 plan, reducing concerns over timing or insider pessimism. Strategically neutral, as it supports executive retention via equity comp in capital-intensive space sector. Investors should monitor aggregate insider activity and Form 4 confirmations for trends, but no immediate red flags.